Brian Cordery, a partner at Bristows who led the external legal team for Novartis

22 September 2026NewsPharmaMarisa Woutersen

Behind the case: How Novartis defended its blockbuster Entresto in the UK

After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Pharma

Boehringer and Dr Reddy’s spar over plausibility as trial wraps up

15 October 2026 A dispute over missing experimental data and patent disclosures draws to a close as Boehringer and Dr Reddy’s deliver their final arguments. The court’s decision could bring greater clarity to the UK approach to plausibility and determine whether Dr Reddy’s can move ahead with its proposed generic launch.

Pharma

Accord’s generic hopes dashed in cyanide antidote ruling

14 October 2026 Efforts to bring a generic cyanide poisoning treatment to market have suffered a setback after a US judge rejected challenges to three patents and criticised the drugmaker’s interpretation of the treatment’s chemical composition.

Pharma

Novo’s semaglutide protection weakens after European ruling

13 October 2026 Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.

More features

Boehringer and Dr Reddy’s spar over plausibility as trial wraps up

Haynes Boone expands in California with new office

Accord’s generic hopes dashed in cyanide antidote ruling

Novo’s semaglutide protection weakens after European ruling

UK to clamp down on non-compete clauses and long notice periods

Boston Scientific expands dispute with J&J unit over cardiac-access technology

Brazilian firm appoints patent strategist to lead department

AIPPI World Congress: ‘Diversity need not be an obstacle to unity’

Behind the case: How Novartis defended its blockbuster Entresto in the UK

More on this story

Editor's picks

Editor's picks

More features